{"id":31983,"date":"2020-07-04T13:09:20","date_gmt":"2020-07-04T12:09:20","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=31983"},"modified":"2021-08-25T12:47:43","modified_gmt":"2021-08-25T11:47:43","slug":"shahram-lavasani","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/","title":{"rendered":"Shahram Lavasani"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n<h2>Shahram Lavasani<\/h2>\n<h4>Founder and CEO at ImmuneBiotech AB<\/h4>\n\t<p>Dr. Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University\/Sweden. With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in multiple sclerosis by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia.<\/p>\n<p>He is the founder of ImmuneBiotech developing novel microbiome therapeutics. The company has access to a proprietary lactobacilli library and advanced selection technologies to design nutritional formulations for optimal management of the diseases. ImmuneBiotech\u00b4s first product GutMagnific<sup>\u00ae<\/sup> has been designed to address the underlying causes of IBS and it is currently investigated, in collaboration with Karolinska Institute, for treatment of chronic fatigue syndrome (ME\/CFS) a neuroimmune condition and a possible long-term effect of Covid-19. GutMagnific<sup>\u00ae<\/sup> has successfully been launched in October 2019.<\/p>\n\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_1.jpg\" alt=\"Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_1\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_1\" onerror=\"this.style.display='none'\" sizes=\"(max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_1-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_1-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_1-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_1-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_1-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_1-315&#215;470.jpg 315w&#8221;>\t\t\t\t\t\t\t\n<h3>\n\tImmuneBiotics for management of neurological conditions &#8211; new clinical evidence\n\t<\/h3>\n\t<p>The presentation will navigate through the translational, clinical, and manufacturing challenges of microbiome-based therapeutics evolving company\u00b4s first product GutMagnific<sup>\u00ae<\/sup> which has successfully been launched in European market in October 2019.<\/p>\n<ul>\n<li>ImmuneBiotics, a new generation of probiotic products designed to boost the immunotherapy treatments.<\/li>\n<li>Translational success of GutMagnific<sup>\u00ae<\/sup> &#8211; a multi-targeted therapeutic microbial consortium &#8211; from the lab to the clinic and to the commercial market.<\/li>\n<li>Clinical evaluation of GutMagnific\u00ae in patients with post-viral fatigue &#8211; a condition considered as a long-term effect of COVID-19<\/li>\n<\/ul>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Shahram Lavasani Founder and CEO at ImmuneBiotech AB Dr. Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University\/Sweden. With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in multiple sclerosis by demonstrating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36566,"parent":31971,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-31983","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Shahram Lavasani &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shahram Lavasani &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-08-25T11:47:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/\",\"name\":\"Shahram Lavasani &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_2.jpg\",\"datePublished\":\"2020-07-04T12:09:20+00:00\",\"dateModified\":\"2021-08-25T11:47:43+00:00\",\"description\":\"Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS).\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_2.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_2.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gut-Brain Axis 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Shahram Lavasani\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shahram Lavasani &#8226; BioTech Pharma Summit","description":"Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/","og_locale":"en_US","og_type":"article","og_title":"Shahram Lavasani &#8226; BioTech Pharma Summit","og_description":"Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS).","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-08-25T11:47:43+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_2.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/","name":"Shahram Lavasani &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_2.jpg","datePublished":"2020-07-04T12:09:20+00:00","dateModified":"2021-08-25T11:47:43+00:00","description":"Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS).","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_2.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2021\/08\/Shahram_Lavasani_BioTech_Pharma_Summit_2021_Profile_2.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/shahram-lavasani\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Gut-Brain Axis 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/gut-brain-axis-speakers\/"},{"@type":"ListItem","position":3,"name":"Shahram Lavasani"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/31983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=31983"}],"version-history":[{"count":8,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/31983\/revisions"}],"predecessor-version":[{"id":36567,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/31983\/revisions\/36567"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/31971"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/36566"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=31983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}